Conray 400

arthrography, peripheral arteriography, intravenous excretory urography + 11 more
Treatment
13 FDA approvals
20 Active Studies for Conray 400

What is Conray 400

Iothalamic acidThe Generic name of this drug
Treatment SummaryIothalamic acid is a medication containing iodine that can be used to make medical images clearer and easier to read.
Glofil-125is the brand name
Conray 400 Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Glofil-125
Iothalamic acid
1983
7

Approved as Treatment by the FDA

Iothalamic acid, otherwise called Glofil-125, is approved by the FDA for 13 uses which include venography and peripheral arteriography .
venography
peripheral arteriography
Bone structure of cranium
computerized tomography
Kidney Diseases
Chronic Kidney Disease (CKD)
Glomerular Filtration Rate (GFR)
arthrography
cerebral angiography
Endoscopic Retrograde Cholangiopancreatography
Cholangiography
angiogram
intravenous excretory urography

When to interrupt dosage

The proposed dosage of Conray 400 is based on the determined condition, including cerebral angiography, venography and cystourethrography. The quantity of dosage is contingent upon the technique of delivery (e.g. Solution or Intra-arterial; Intravenous) specified in the table underneath.
Condition
Dosage
Administration
arthrography
, 0.275 mCi/mL, 54.3 %, 66.8 %, 172.0 mg/mL, 300.0 mg/mL, 600.0 mg/mL, 430.0 mg/mL, 668.0 mg/mL, 1.0 mg, 780.0 mg/mL, 260.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Intravascular, Solution, Solution - Intravascular, Urethral, Solution - Urethral, Liquid - Urethral, Liquid, Intra-arterial; Intravenous, Solution - Intra-arterial; Intravenous, Solution - Intravenous, Ureteral, Injection, Injection - Ureteral, Injection - Intravascular, Injection - Intravenous
peripheral arteriography
, 0.275 mCi/mL, 54.3 %, 66.8 %, 172.0 mg/mL, 300.0 mg/mL, 600.0 mg/mL, 430.0 mg/mL, 668.0 mg/mL, 1.0 mg, 780.0 mg/mL, 260.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Intravascular, Solution, Solution - Intravascular, Urethral, Solution - Urethral, Liquid - Urethral, Liquid, Intra-arterial; Intravenous, Solution - Intra-arterial; Intravenous, Solution - Intravenous, Ureteral, Injection, Injection - Ureteral, Injection - Intravascular, Injection - Intravenous
intravenous excretory urography
, 0.275 mCi/mL, 54.3 %, 66.8 %, 172.0 mg/mL, 300.0 mg/mL, 600.0 mg/mL, 430.0 mg/mL, 668.0 mg/mL, 1.0 mg, 780.0 mg/mL, 260.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Intravascular, Solution, Solution - Intravascular, Urethral, Solution - Urethral, Liquid - Urethral, Liquid, Intra-arterial; Intravenous, Solution - Intra-arterial; Intravenous, Solution - Intravenous, Ureteral, Injection, Injection - Ureteral, Injection - Intravascular, Injection - Intravenous
venography
, 0.275 mCi/mL, 54.3 %, 66.8 %, 172.0 mg/mL, 300.0 mg/mL, 600.0 mg/mL, 430.0 mg/mL, 668.0 mg/mL, 1.0 mg, 780.0 mg/mL, 260.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Intravascular, Solution, Solution - Intravascular, Urethral, Solution - Urethral, Liquid - Urethral, Liquid, Intra-arterial; Intravenous, Solution - Intra-arterial; Intravenous, Solution - Intravenous, Ureteral, Injection, Injection - Ureteral, Injection - Intravascular, Injection - Intravenous
computerized tomography
, 0.275 mCi/mL, 54.3 %, 66.8 %, 172.0 mg/mL, 300.0 mg/mL, 600.0 mg/mL, 430.0 mg/mL, 668.0 mg/mL, 1.0 mg, 780.0 mg/mL, 260.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Intravascular, Solution, Solution - Intravascular, Urethral, Solution - Urethral, Liquid - Urethral, Liquid, Intra-arterial; Intravenous, Solution - Intra-arterial; Intravenous, Solution - Intravenous, Ureteral, Injection, Injection - Ureteral, Injection - Intravascular, Injection - Intravenous
cerebral angiography
, 0.275 mCi/mL, 54.3 %, 66.8 %, 172.0 mg/mL, 300.0 mg/mL, 600.0 mg/mL, 430.0 mg/mL, 668.0 mg/mL, 1.0 mg, 780.0 mg/mL, 260.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Intravascular, Solution, Solution - Intravascular, Urethral, Solution - Urethral, Liquid - Urethral, Liquid, Intra-arterial; Intravenous, Solution - Intra-arterial; Intravenous, Solution - Intravenous, Ureteral, Injection, Injection - Ureteral, Injection - Intravascular, Injection - Intravenous
retrograde cystography
, 0.275 mCi/mL, 54.3 %, 66.8 %, 172.0 mg/mL, 300.0 mg/mL, 600.0 mg/mL, 430.0 mg/mL, 668.0 mg/mL, 1.0 mg, 780.0 mg/mL, 260.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Intravascular, Solution, Solution - Intravascular, Urethral, Solution - Urethral, Liquid - Urethral, Liquid, Intra-arterial; Intravenous, Solution - Intra-arterial; Intravenous, Solution - Intravenous, Ureteral, Injection, Injection - Ureteral, Injection - Intravascular, Injection - Intravenous
angiogram
, 0.275 mCi/mL, 54.3 %, 66.8 %, 172.0 mg/mL, 300.0 mg/mL, 600.0 mg/mL, 430.0 mg/mL, 668.0 mg/mL, 1.0 mg, 780.0 mg/mL, 260.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Intravascular, Solution, Solution - Intravascular, Urethral, Solution - Urethral, Liquid - Urethral, Liquid, Intra-arterial; Intravenous, Solution - Intra-arterial; Intravenous, Solution - Intravenous, Ureteral, Injection, Injection - Ureteral, Injection - Intravascular, Injection - Intravenous
Bone structure of cranium
, 0.275 mCi/mL, 54.3 %, 66.8 %, 172.0 mg/mL, 300.0 mg/mL, 600.0 mg/mL, 430.0 mg/mL, 668.0 mg/mL, 1.0 mg, 780.0 mg/mL, 260.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Intravascular, Solution, Solution - Intravascular, Urethral, Solution - Urethral, Liquid - Urethral, Liquid, Intra-arterial; Intravenous, Solution - Intra-arterial; Intravenous, Solution - Intravenous, Ureteral, Injection, Injection - Ureteral, Injection - Intravascular, Injection - Intravenous
Chronic Kidney Disease (CKD)
, 0.275 mCi/mL, 54.3 %, 66.8 %, 172.0 mg/mL, 300.0 mg/mL, 600.0 mg/mL, 430.0 mg/mL, 668.0 mg/mL, 1.0 mg, 780.0 mg/mL, 260.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Intravascular, Solution, Solution - Intravascular, Urethral, Solution - Urethral, Liquid - Urethral, Liquid, Intra-arterial; Intravenous, Solution - Intra-arterial; Intravenous, Solution - Intravenous, Ureteral, Injection, Injection - Ureteral, Injection - Intravascular, Injection - Intravenous
Endoscopic Retrograde Cholangiopancreatography
, 0.275 mCi/mL, 54.3 %, 66.8 %, 172.0 mg/mL, 300.0 mg/mL, 600.0 mg/mL, 430.0 mg/mL, 668.0 mg/mL, 1.0 mg, 780.0 mg/mL, 260.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Intravascular, Solution, Solution - Intravascular, Urethral, Solution - Urethral, Liquid - Urethral, Liquid, Intra-arterial; Intravenous, Solution - Intra-arterial; Intravenous, Solution - Intravenous, Ureteral, Injection, Injection - Ureteral, Injection - Intravascular, Injection - Intravenous
Glomerular Filtration Rate (GFR)
, 0.275 mCi/mL, 54.3 %, 66.8 %, 172.0 mg/mL, 300.0 mg/mL, 600.0 mg/mL, 430.0 mg/mL, 668.0 mg/mL, 1.0 mg, 780.0 mg/mL, 260.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Intravascular, Solution, Solution - Intravascular, Urethral, Solution - Urethral, Liquid - Urethral, Liquid, Intra-arterial; Intravenous, Solution - Intra-arterial; Intravenous, Solution - Intravenous, Ureteral, Injection, Injection - Ureteral, Injection - Intravascular, Injection - Intravenous
cystourethrography
, 0.275 mCi/mL, 54.3 %, 66.8 %, 172.0 mg/mL, 300.0 mg/mL, 600.0 mg/mL, 430.0 mg/mL, 668.0 mg/mL, 1.0 mg, 780.0 mg/mL, 260.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Intravascular, Solution, Solution - Intravascular, Urethral, Solution - Urethral, Liquid - Urethral, Liquid, Intra-arterial; Intravenous, Solution - Intra-arterial; Intravenous, Solution - Intravenous, Ureteral, Injection, Injection - Ureteral, Injection - Intravascular, Injection - Intravenous
Cholangiography
, 0.275 mCi/mL, 54.3 %, 66.8 %, 172.0 mg/mL, 300.0 mg/mL, 600.0 mg/mL, 430.0 mg/mL, 668.0 mg/mL, 1.0 mg, 780.0 mg/mL, 260.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Intravascular, Solution, Solution - Intravascular, Urethral, Solution - Urethral, Liquid - Urethral, Liquid, Intra-arterial; Intravenous, Solution - Intra-arterial; Intravenous, Solution - Intravenous, Ureteral, Injection, Injection - Ureteral, Injection - Intravascular, Injection - Intravenous

Warnings

Conray 400 has seven contraindications, and it should not be used when enduring the conditions indicated in the following table.Conray 400 Contraindications
Condition
Risk Level
Notes
myelography
Do Not Combine
Pancreatitis
Do Not Combine
Prothrombin time prolongation
Do Not Combine
Endoscopy (procedure)
Do Not Combine
infection near the joint
Do Not Combine
Blood Coagulation Disorders
Do Not Combine
Cholangitis
Do Not Combine
There are 20 known major drug interactions with Conray 400.
Common Conray 400 Drug Interactions
Drug Name
Risk Level
Description
Acrivastine
Minor
Iothalamic acid may decrease the excretion rate of Acrivastine which could result in a higher serum level.
Albutrepenonacog alfa
Minor
Iothalamic acid may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.
Almasilate
Minor
Iothalamic acid may decrease the excretion rate of Almasilate which could result in a higher serum level.
Antihemophilic factor (recombinant), PEGylated
Minor
Iothalamic acid may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.
Antithrombin III human
Minor
Iothalamic acid may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.

Conray 400 Novel Uses: Which Conditions Have a Clinical Trial Featuring Conray 400?

236 active trials are being conducted to explore the utility of Conray 400 for venography, Glomerular Filtration Rate (GFR) estimation and angiogram.
Condition
Clinical Trials
Trial Phases
cystourethrography
0 Actively Recruiting
peripheral arteriography
0 Actively Recruiting
Endoscopic Retrograde Cholangiopancreatography
0 Actively Recruiting
cerebral angiography
0 Actively Recruiting
Bone structure of cranium
0 Actively Recruiting
Chronic Kidney Disease (CKD)
27 Actively Recruiting
Phase 3, Not Applicable, Phase 2, Phase 4, Phase 1
intravenous excretory urography
0 Actively Recruiting
angiogram
0 Actively Recruiting
Glomerular Filtration Rate (GFR)
0 Actively Recruiting
Cholangiography
0 Actively Recruiting
venography
0 Actively Recruiting
computerized tomography
1 Actively Recruiting
Not Applicable
retrograde cystography
0 Actively Recruiting
arthrography
0 Actively Recruiting

Patient Q&A Section about conray 400

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Conray used for?

"Conray is a contrast agent used in diagnostic procedures such as excretory urography, cerebral angiography, peripheral arteriography, venography, arthrography, direct cholangiography, endoscopic retrograde cholangiopancreatography, and cranial computerized angiotomography. It is also used to enhance computed tomographic brain images."

Answered by AI

What is Conray 43 used for?

"Conray 43 is a diagnostic tool that uses radiopaque medium to create images of the lower extremities, urinary tract, brain, and arteries."

Answered by AI

What is Vasodilan used for?

"This medication is typically used in conjunction with other treatments for blood vessel diseases such as arteriosclerosis obliterans, Raynaud's disease, Buerger's disease, and cerebrovascular insufficiency."

Answered by AI

How is Conray administered?

"This medication may be given in two ways- all at once (bolus injection), or over a period of time (rapid infusion). The usual dose for adults and children is 0.5-1 mL per kilogram of body weight. For the bolus injection, the medication should be injected at a rate of 2 mL per second, and scanning should begin immediately after administration. This dose may be given more than once if necessary."

Answered by AI

Clinical Trials for Conray 400

Have you considered Conray 400 clinical trials? We made a collection of clinical trials featuring Conray 400, we think they might fit your search criteria.
Have you considered Conray 400 clinical trials? We made a collection of clinical trials featuring Conray 400, we think they might fit your search criteria.
Have you considered Conray 400 clinical trials? We made a collection of clinical trials featuring Conray 400, we think they might fit your search criteria.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top